Astellas Pharma Inc. (ALPMY)
USD 9.54
(-1.14%)
USD 9.54
(-1.14%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 | 447.73 Billion JPY | 795.48% |
| 2023 | 50 Billion JPY | 7296.45% |
| 2022 | 676 Million JPY | -99.16% |
| 2021 | 80 Billion JPY | 2446.15% |
| 2020 | 3.14 Billion JPY | 34.22% |
| 2019 | 2.34 Billion JPY | -47.02% |
| 2018 | 4.41 Billion JPY | 180.39% |
| 2017 | 1.57 Billion JPY | -32.1% |
| 2016 | 2.32 Billion JPY | 224.16% |
| 2015 | 716 Million JPY | -11.93% |
| 2014 | 813 Million JPY | 10.31% |
| 2013 | 737 Million JPY | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q2 | 473.05 Billion JPY | 850.71% |
| 2024 Q1 | 50 Billion JPY | 0.0% |
| 2024 Q4 | 447.73 Billion JPY | 11.75% |
| 2024 FY | 447.73 Billion JPY | 795.48% |
| 2024 Q3 | 463.8 Billion JPY | -1.98% |
| 2023 Q3 | 4.37 Billion JPY | -12.84% |
| 2023 Q2 | 5.02 Billion JPY | 3.14% |
| 2023 Q1 | 4.87 Billion JPY | -91.26% |
| 2023 Q4 | 50 Billion JPY | 1042.07% |
| 2023 FY | 50 Billion JPY | 7296.45% |
| 2022 Q1 | 308 Million JPY | -99.62% |
| 2022 FY | 676 Million JPY | -99.16% |
| 2022 Q4 | 55.69 Billion JPY | 8287.05% |
| 2022 Q2 | 444 Million JPY | 44.16% |
| 2022 Q3 | 664 Million JPY | 49.55% |
| 2021 FY | 80 Billion JPY | 2446.15% |
| 2021 Q4 | 80 Billion JPY | 6320.55% |
| 2021 Q3 | 1.24 Billion JPY | -54.66% |
| 2021 Q1 | 2.82 Billion JPY | -96.1% |
| 2021 Q2 | 2.74 Billion JPY | -2.62% |
| 2020 FY | 3.14 Billion JPY | 34.22% |
| 2020 Q1 | 1.59 Billion JPY | -31.78% |
| 2020 Q2 | 2.96 Billion JPY | 85.72% |
| 2020 Q3 | 3.15 Billion JPY | 6.3% |
| 2020 Q4 | 72.36 Billion JPY | 2195.24% |
| 2019 Q2 | 3.87 Billion JPY | 10.57% |
| 2019 FY | 2.34 Billion JPY | -47.02% |
| 2019 Q4 | 2.34 Billion JPY | 48.92% |
| 2019 Q3 | 1.57 Billion JPY | -59.4% |
| 2019 Q1 | 3.5 Billion JPY | -20.75% |
| 2018 Q3 | 3.76 Billion JPY | 0.03% |
| 2018 FY | 4.41 Billion JPY | 180.39% |
| 2018 Q4 | 4.41 Billion JPY | 17.5% |
| 2018 Q2 | 3.76 Billion JPY | -0.21% |
| 2018 Q1 | 3.76 Billion JPY | 139.09% |
| 2017 Q2 | 869 Million JPY | -24.96% |
| 2017 Q1 | 1.15 Billion JPY | -50.11% |
| 2017 FY | 1.57 Billion JPY | -32.1% |
| 2017 Q4 | 1.57 Billion JPY | 87.17% |
| 2017 Q3 | 842 Million JPY | -3.11% |
| 2016 Q1 | 925 Million JPY | 29.19% |
| 2016 Q3 | 1.71 Billion JPY | -2.23% |
| 2016 Q4 | 2.32 Billion JPY | 35.49% |
| 2016 Q2 | 1.75 Billion JPY | 89.41% |
| 2016 FY | 2.32 Billion JPY | 224.16% |
| 2015 Q2 | 72 Million JPY | 0.0% |
| 2015 Q1 | 72 Million JPY | -91.14% |
| 2015 FY | 716 Million JPY | -11.93% |
| 2015 Q4 | 716 Million JPY | 695.56% |
| 2015 Q3 | 90 Million JPY | 25.0% |
| 2014 Q3 | - JPY | 0.0% |
| 2014 Q1 | - JPY | -100.0% |
| 2014 Q2 | - JPY | 0.0% |
| 2014 FY | 813 Million JPY | 10.31% |
| 2014 Q4 | 813 Million JPY | 0.0% |
| 2013 Q2 | - JPY | 0.0% |
| 2013 Q3 | - JPY | 0.0% |
| 2013 Q4 | 737 Million JPY | 0.0% |
| 2013 FY | 737 Million JPY | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| AstraZeneca PLC | 22.33 Billion USD | -1904.789% |
| Bristol-Myers Squibb Company PFD CONV 2 | 38.18 Billion USD | -1072.611% |
| CSPC Pharmaceutical Group Limited | 107.05 Million USD | -418120.03% |
| Clarus Therapeutics Holdings, Inc. | - USD | -Infinity% |
| Novartis AG | 20.03 Billion USD | -2134.891% |
| PT Kalbe Farma Tbk. | 19.39 Million USD | -2308792.333% |